Table 4 Percentage of DREAM patients eligible for the RCTs on the basis of disease activity
StudyCriteria for active RA in RCTsNo. of eligible DREAM patients (%)
Adalimumab + MTX
Weinblatt, 200316⩾9(/68) TJ, ⩾6(/66) SJ146/186 (78.5%)
Furst, 200318⩾6(/68) TJ, ⩾6(/66) SJ138/186 (74.2%
Keystone, 200417⩾9(/68) TJ, ⩾6(/66) SJ, CRP >1 mg/dl, RF+61/186 (32.8%)
Adalimumab mono
Van de Putte, 200319⩾12(/68) TJ, ⩾10(/66), ESR⩾28 or CRP ⩾2 mg/dl9/31 (29.0%)
Van de Putte, 200420⩾ 12(/68) TJ, ⩾10(/66), ESR⩾28 or CRP ⩾2 mg/dl9/31 (29.0%)
Etanercept + MTX
Weinblatt, 199910⩾6(/71) TJ, ⩾6(/68) SJ126/171 (73.7%)
Lan, 200411⩾6(/28) TJ, ⩾6(/28) SJ87/171 (50.9)
Etanercept mono
Moreland, 19974⩾12(/71) TJ, ⩾10(/68) SJ, ESR ⩾28 or CRP >2 mg/dl18/45 (40.0%)
Moreland, 199912⩾12(/71) TJ, ⩾10(/68) SJ, ESR ⩾28 or CRP >2 mg/dl18/45 (40.0%)
Keystone, 200413⩾6(/71) TJ, ⩾6(/68) SJ36/45 (80.0%)
Infliximab + MTX
Maini, 199814⩾6(/68) TJ and at least two of the following ⩾6(/66) SJ, ESR >28, CRP >1.5 mg/dl49/103 (47.6%)
ATTRACT, 99-0415⩾6(/68) TJ, ⩾6(/66) SJ, ESR >28 or CRP >2 mg/dl44/103 (42.7%)
  • CRP, C-reactive protein; DREAM, Dutch Rheumatoid Arthritis Monitoring; ESR, erythrocyte sedimentation rate; MTX, methotrexate; RA, rheumatoid arthritis; RCT, randomised controlled trial; RF, rheumatoid factor; SJ, swollen joints; TJ, tender joints.